BCM
ZVRA icon

Boyle Capital Management’s Zevra Therapeutics ZVRA Stock Holding History

Boyle Capital Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-1,810
Closed -$420K – 27
2016
Q1 		$420K Sell
1,810
-321
-15% -$77.7K 0.5% 17
2015
Q4 		$677K Buy
+2,131
New +$579K 0.93% 12

Other funds holding ZVRA

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
AWA
Arete Wealth Advisors Chicago, Illinois $1.51B AUM 33.02% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

Boyle Capital Management's ZVRA Position: Q2 2016 in Review

Boyle Capital Management sold out of Zevra Therapeutics (ZVRA) in Q2 2016, closing a stake of 1,810 shares — an estimated $420K sold.

Boyle Capital Management first reported a position in ZVRA in Q4 2015 and held it in 2 quarters. The position peaked at $677K in Q4 2015. 40 funds tracked by Wall St. Rank hold ZVRA as of Q2 2016.

  • Boyle Capital Management reported no remaining Zevra Therapeutics position as of Q2 2016 after selling out during the quarter.
  • Boyle Capital Management sold 1,810 Zevra Therapeutics shares in Q2 2016, an estimated $420K.
  • Boyle Capital Management first reported a position in Zevra Therapeutics in Q4 2015 and held it in 2 quarters.
  • Boyle Capital Management's Zevra Therapeutics position peaked at $677K in Q4 2015.
  • 40 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2016.

Based on Boyle Capital Management's 13F filing for Q2 2016, filed 12 Aug 2016.